Financial Performance - Sales for the three-month period ended March 31, 2021 increased approximately 0.7% to $48.6 million from $48.3 million in the same period last year[68]. - Gross margin decreased to 25.9% for the three-month period ended March 31, 2021, down from 26.6% in the same period last year[77]. - Operating income and net income increased by 4.4% and 7.0%, respectively, for the three-month period ended March 31, 2021[68]. - Sales to customers in the Aerospace & defense and Consumer markets increased by 68.2% and 62.1%, respectively, while sales to the Medical market decreased by 11.5%[76]. - Selling, general, and administrative expenses decreased approximately 5.7% to $7.3 million for the three-month period ended March 31, 2021[78]. Cash Flow and Investments - Net cash provided by operations for the three-month period ended March 31, 2021 was approximately $3.3 million[83]. - Net cash used in investing activities during the three-month period ended March 31, 2021 was approximately $1.4 million, primarily for manufacturing machinery and equipment[84]. - As of March 31, 2021, the Company generated approximately $3.3 million in cash from operations during the three months[92]. Liquidity and Financial Position - The Company has a strong liquidity position and solid balance sheet, enabling effective management through the COVID-19 pandemic[74]. - The Company amended its credit agreement, extending the maturity date from February 1, 2023, to December 31, 2025[87]. - The credit facilities include a $20 million unsecured term loan and a $50 million unsecured revolving credit facility[88]. - The Company has no amounts outstanding under the credit agreement as of March 31, 2021[89]. - The Company is subject to a minimum fixed-charge coverage financial covenant and a maximum total funded debt to EBITDA financial covenant[89]. Future Strategy and Plans - The Company’s current strategy includes further organic growth and growth through strategic acquisitions[67]. - The Company plans to enhance manufacturing efficiencies and may consider additional acquisitions throughout fiscal 2021[93]. - The Company anticipates future capital requirements could be substantial for expansions or acquisitions[94]. - The Company has approximately $9.4 million available for future stock repurchases under its authorized program as of March 31, 2021[95]. - The Company has not repurchased any shares under its stock repurchase program in the first three months of 2021[95]. Other Financial Information - The Company deferred social security payments of approximately $1.6 million through December 31, 2020, with 50% due by December 31, 2021[75]. - The fair value of the interest rate swap agreement was approximately $(385) thousand as of March 31, 2021[90].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-12648 UFP Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 04-2314970 (State or oth ...

Financial Performance - Net sales for the three months ended September 30, 2020, were $43.299 million, a decrease of 12.5% compared to $49.394 million for the same period in 2019[11]. - Gross profit for the nine months ended September 30, 2020, was $33.301 million, down 17.2% from $40.188 million in the same period of 2019[11]. - Net income for the three months ended September 30, 2020, was $2.988 million, a decline of 47.0% compared to $5.641 million for the same period in 2019[11]. - Basic net income per share for the nine months ended September 30, 2020, was $1.23, down from $1.88 in the same period of 2019, reflecting a decrease of 34.6%[11]. - Operating income for the nine months ended September 30, 2020, was $11.795 million, down 34.3% from $17.962 million in the same period of 2019[11]. - Net income for the nine months ended September 30, 2020, was $9,197 thousand, a decrease of 34.5% compared to $13,973 thousand in 2019[18]. - Total net sales for the nine months ended September 30, 2020, were $134,220 thousand, down 9.4% from $148,120 thousand in 2019[27]. - Cash flows from operating activities for the nine months ended September 30, 2020, were $16,738 thousand, a decrease of 25.4% from $22,386 thousand in 2019[18]. Assets and Equity - Total assets increased to $200.664 million as of September 30, 2020, up from $188.758 million at December 31, 2019, representing a growth of 6.4%[9]. - Total current assets rose to $68.563 million as of September 30, 2020, compared to $53.250 million at December 31, 2019, marking an increase of 28.7%[9]. - Total stockholders' equity increased to $172.439 million as of September 30, 2020, up from $161.991 million at December 31, 2019, indicating a growth of 6.9%[9]. - Cash and cash equivalents significantly increased to $17.435 million as of September 30, 2020, compared to $3.743 million at December 31, 2019, reflecting a growth of 366.5%[9]. - Total inventory as of September 30, 2020, was $19,488 thousand, an increase from $18,276 thousand as of December 31, 2019[49]. Revenue and Sales - Medical market sales for the three months ended September 30, 2020, were $26,850 thousand, representing 62.0% of total sales, compared to $32,175 thousand in 2019[56]. - The company recognized revenue from engineering services of $3,157 thousand for the nine months ended September 30, 2020, compared to $1,814 thousand in 2019, reflecting a growth of 74.0%[27]. Expenses and Losses - The company reported a loss on disposal of fixed assets amounting to $12, compared to no loss in the same period of 2019[11]. - The allowance for credit losses at the end of the nine months ended September 30, 2020, was $649 thousand, an increase of 33.5% from $486 thousand at the beginning of the period[35]. - The company incurred cash paid for interest of $55 thousand for the nine months ended September 30, 2020, significantly down from $579 thousand in 2019[31]. - The total lease cost for the nine months ended September 30, 2020, was $1,100 thousand, slightly down from $1,105 thousand in 2019[52]. Stock and Compensation - Total share-based compensation for the three months ended September 30, 2020, was $239 thousand, a decrease from $473 thousand in 2019, while for the nine months, it increased to $1,338 thousand from $1,169 thousand[42]. - The total intrinsic value of all options exercised during the nine-month periods ended September 30, 2020, was approximately $757 thousand, down from $867 thousand in 2019[45]. - As of September 30, 2020, the Company had approximately $2.3 million of unrecognized compensation expense expected to be recognized over 3.5 years[48]. Debt and Financing - The Company has an unsecured $70 million Amended and Restated Credit Agreement, which includes a $20 million unsecured term loan and a $50 million revolving credit facility[59]. - As of September 30, 2020, the applicable interest rate under the Amended and Restated Credit Agreement was approximately 1.14%, and the Company was in compliance with all covenants[61]. - The Company entered into a $20 million, 5-year interest rate swap agreement to convert the interest on the term loan from a variable rate to a fixed rate, with a notional amount of approximately $12.1 million as of September 30, 2020[62]. - The fair value of the interest rate swap as of September 30, 2020, was approximately $(538) thousand, reflecting a change in fair value recorded as an expense[62]. - The Company is subject to a minimum fixed-charge coverage financial covenant and a maximum total funded debt to EBITDA financial covenant under the Amended and Restated Credit Agreement[61]. Tax and Amortization - The Company recorded an income tax expense of approximately 19.4% for the three-month period ended September 30, 2020, compared to 5.2% for the same period in 2019[58]. - The Company recorded amortization expense related to intangible assets of approximately $314 thousand for both the three-month periods ended September 30, 2020 and 2019[57]. - The estimated remaining amortization expense as of September 30, 2020, totals $20,032 thousand, with $314 thousand expected for the remainder of 2020[57]. Other Financial Information - Deferred revenue at the end of the nine months ended September 30, 2020, was $1,946 thousand, down 23.1% from $2,532 thousand in 2019[28]. - Unbilled receivables at the end of the nine months ended September 30, 2020, increased to $291 thousand from $13 thousand in 2019[30]. - The weighted average number of diluted common shares outstanding for the three months ended September 30, 2020, was 7,555 thousand, compared to 7,493 thousand in 2019[54]. - The weighted average discount rate for finance leases as of September 30, 2020, was 2.26%[52]. - The Financial Conduct Authority announced plans to phase out LIBOR by the end of 2021, which may require the Company to amend certain contracts[63].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-12648 UFP Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 04-2314970 (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2020 OR UFP Technologies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Delaware 04-2314970 100 Hale Street, Newburyport, MA 01950, USA (Address of principal executive offi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-12648 UFP Technologies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended SEPTEMBER 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-12648 UFP Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 04-2314970 (Stat ...

Welcome Investors August 28, 2019 Safe Harbor Statement Nasdaq: UFPT This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company's prospects, anticipated advantages the Company expects to realize from its acquisition strategies, the Company's financial performance, targets and goals, participation in multiple markets, its engineering and product development resources, the Company's business opportunities, the Company's growth potential ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2019 OR _________________________________________ (Former name, former address, and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 193 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-12648 UFP Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 04-2314970 (State or ...